Chime Biologics, a global CDMO, has announced a strategic collaboration with MedPacto, a South Korean clinically staged company.
 
MedPacto, known for its focus on cancer therapeutics, will leverage Chime Biologics’ expertise in biologics development to streamline the process from tech transfer to cGMP clinical manufacturing for Investigational New Drug (IND) submissions. Under the agreement, Chime Biologics will advance the Chemistry, Manufacturing, and Controls (CMC) process development for multiple preclinical drug candidates.
 
Dr. Jungwon Woo, President of MedPacto, said, “We are highly impressed by Chime Biologics’ development and manufacturing expertise, which is crucial in helping us expand into major global markets. Their ability to meet international standards will greatly support our efforts to advance our assets into a new stage. This collaboration is a key step forward, and we look forward to a successful and long-term partnership.”
 
Dr. Jimmy Wei, President of Chime Biologics, added, “We are pleased to announce our strategic collaboration with MedPacto, a respected KOSDAQ-listed company with a strong portfolio of first-in-class assets. This partnership marks the beginning of a long-term relationship aimed at advancing pharmaceutical innovation. It aligns with our growth strategy in South Korea and aligns with our commitment to the region’s biopharmaceutical landscape. We look forward to working closely with MedPacto and contributing to the success of their innovative pipeline.”
 
Chime Biologics is increasing its manufacturing capacity to 100,000 liters to strengthen its position as a global CDMO. The company is entering the South Korean market and has signed agreements with several local biotech firms for antibody drugs and biosimilars.